ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP)

40.72
0.335
(0.83%)
Closed December 22 4:00PM
41.00
0.28
(0.69%)
After Hours: 7:56PM

Professional-Grade Tools, for Individual Investors.

CRSP News

Official News Only

CRSP Discussion

View Posts
PonkenPlonken PonkenPlonken 2 weeks ago
cheap cheap
👍️ 1
jondoeuk jondoeuk 2 weeks ago
The PR https://www.globenewswire.com/news-release/2024/12/09/2993974/0/en/CRISPR-Therapeutics-Presents-Data-at-the-2024-American-Society-of-Hematology-ASH-Annual-Meeting.html

Poster https://ir.crisprtx.com/static-files/12114290-21a6-4544-9cb7-de4fe2852e94
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 3 weeks ago
Neglected ugly duckling. $NTLA, $VERV & $CRBU now do trials outside of the US.... Maybe sentiment change is on the horizon -- see below

"The CBER director also apologized for β€œmistakes” in how the FDA handled early work for in vivo gene therapies, which β€œled to offshoring of some of the trials.”"
https://endpts.com/fda-vaccine-chief-peter-marks-pledges-to-stay-as-long-as-hes-welcome/#:~:text=The%20CBER%20director%20also%20apologized,%E2%80%9Cit%20is%20really%20important.%E2%80%9D

CHEAP CHEAP
SRPT and BMS announcing nice CRISPR deals with ARWR and PRME should help this too!
πŸ‘οΈ0
jondoeuk jondoeuk 3 weeks ago
CTX130 data in R/R T-cell lymphomas (peripheral T-cell lymphoma or cutaneous T-cell lymphoma) https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00508-4/abstract

The ORR was 46.2%. Of those treated at DL3 and higher, the ORR was 51.6%.
👍️ 1
PonkenPlonken PonkenPlonken 4 weeks ago
so so so undervalued and misunderstood i believe...... frankly just cheap
https://x.com/RNAiAnalyst/status/1859876294487363651
👍️ 1
jondoeuk jondoeuk 1 month ago
They now have the ability to put in eight to nine edits. So it is a single cassette that expresses the CAR, can express a cytokine and has an shRNA-like approach to knock down genes. So there's no theoretical limit as to the number of edits, but there may be marginal utility beyond a certain point.

Hopefully, they look to improve donor selection, cell selection and manufacturing, as all could increase efficacy.
👍️ 1
jondoeuk jondoeuk 2 months ago
ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
CRSP 10Q 11/5
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
CRSP under $50
πŸ‘οΈ0
jondoeuk jondoeuk 2 months ago
OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082
👍️ 1
TechandBio TechandBio 3 months ago
CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
Buy range again thanks a bunch
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
Buy range again thanks a bunch
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 3 months ago
Hi MD,
Here's a little longer view:


This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
CRSP trend since February remains bearish
πŸ‘οΈ0
jondoeuk jondoeuk 5 months ago
Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html
πŸ‘οΈ0
lambchops lambchops 5 months ago
Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
CRSP under $75
πŸ‘οΈ0
TechandBio TechandBio 5 months ago
Crispr added some $120 Vertical debit spreads in 2026

$CRSP
👍️ 1
axelvento axelvento 7 months ago
I agree.....solid company$$$$$$$$
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero
👍️ 1
axelvento axelvento 7 months ago
Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html
πŸ‘οΈ0
jondoeuk jondoeuk 8 months ago
https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 8 months ago
StockCharts 3 year history with 20% ZigZag reversals................



CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG
πŸ‘οΈ0
OldAIMGuy OldAIMGuy 8 months ago
Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
CRSP over $30
πŸ‘οΈ0
jondoeuk jondoeuk 9 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
CRSP new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
CRSP new 52 week high
👍️ 1
Monksdream Monksdream 10 months ago
CRSP new 52 week high
👍️ 1
jondoeuk jondoeuk 10 months ago
They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html
👍️ 1
Monksdream Monksdream 10 months ago
Didn’t tank like BLUE
Recovered


More analysis from Nanolyze

πŸ‘οΈ0
Monksdream Monksdream 11 months ago
So there has been some discussion since my last post
More in this podcast
🌈 1 🍆 1
jondoeuk jondoeuk 11 months ago
Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html
👍️ 1
jondoeuk jondoeuk 11 months ago
Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html
πŸ‘οΈ0
jondoeuk jondoeuk 12 months ago
Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true
👍️ 1
jondoeuk jondoeuk 12 months ago
Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html
πŸ‘οΈ0
JJ8 JJ8 1 year ago
Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY
👍️ 1
OldAIMGuy OldAIMGuy 1 year ago
Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG
πŸ‘οΈ0
JJ8 JJ8 1 year ago
CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing
πŸ‘οΈ0
JJ8 JJ8 1 year ago
Windbag1014,

Thanks for your views and informative response. GLTY & GLTA
πŸ‘οΈ0
JJ8 JJ8 1 year ago
OldAIMGuy,

Thanks for your clear and detailed response.

Your approach and strategy dealing with what Crispr T AG stock price movement over time shows, and the Crispr company activity makes good sense. More power and good luck to you.

John
👍️ 1
OldAIMGuy OldAIMGuy 1 year ago
Hi JJ8, Re: CRSP price action..........................

My guess is it's a "Sell on the News" action. This isn't the first time CRSP has shown high amplitude price change as this histogram shows:
https://schrts.co/NSfSbXYF

I think it will be important to watch the transition of this company from basically a 'research' business to one of product development and distribution. Somewhere along the way they'll have to show a profit to reward those who've invested in them. I'm fond of watching the Accumulation/Distribution activity to see what is happening with strong and weak hands holding the stock. In the mean time I plan on trimming and backfilling my position as the price moves around. I last added 12% to my position at $47.56 in August and had the opportunity to part with 10% of the holding at $69.57 a few weeks ago. The core position remains.



With each cycle of the price the portfolio builds out a bit.

Hope this helps,
OAG
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock